Clinical trials - Cancer Research SA

Filter By

VS-6766-301

Phase 3

Open and recruiting

Ovarian cancer – Recurrent Low-Grade Serous Ovarian Cancer

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Read more: Ovarian cancer – Recurrent Low-Grade Serous Ovarian Cancer
RAD204

Phase 1, Phase 1a, Phase 1b

Open and recruiting

NSCLC – Theranostics – 177Lu-RAD204

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer
Read more: NSCLC – Theranostics – 177Lu-RAD204
LOXO-RAS-20001

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Solid Tumours – LY3537982 – KRAS G12C-Mutant cancers

LOXO-KRAS: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Read more: Solid Tumours – LY3537982 – KRAS G12C-Mutant cancers
LOXO-FRA-24001

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Ovarian cancer – LY4170156 – ADC Targeting Folate Receptor

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor a -Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
Read more: Ovarian cancer – LY4170156 – ADC Targeting Folate Receptor
BNT113-01 AHEAD-MERIT

Phase 2

Open and recruiting

Head and Neck SCC – 1st line – HPV16+ expressing PDL1

An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
Read more: Head and Neck SCC – 1st line – HPV16+ expressing PDL1
AMT-562

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours – Anti-HER3 ADC

First-in-Human, Phase 1 Study of AMT-562, an Anti-HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Read more: Advanced Solid Tumours – Anti-HER3 ADC
Tumorad-01 Spago

Phase 1

Open and recruiting

Advanced Solid Tumours – Theranostics – Tumorad-01 [177Lu]Lu- SN201

A Phase I/IIa, dose escalation and dose expansion, first-in-human, open-label, multicenter, single-arm study evaluating the safety, tolerability, dosimetry, and early efficacy of [177Lu]Lu- SN201 in participants with progressive or treatment-refractory locally advanced unresectable, metastatic or recurrent solid tumors.
Read more: Advanced Solid Tumours – Theranostics – Tumorad-01 [177Lu]Lu- SN201
DURAVELO-02: BT8009-230

Phase 2, Phase 3

Open and recruiting

Urothelial Cancer – BT8009 Monotherapy or Combo

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer
Read more: Urothelial Cancer – BT8009 Monotherapy or Combo
BG-C477-101 CEACAM5

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumors – BG-C477 – High CEA

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors
Read more: Advanced Solid Tumors – BG-C477 – High CEA